Sign in
Taking people in PolandPhase 1

Safety and Effects of LFD-200 in Healthy People and People With Rheumatoid Arthritis

Tests different doses of LFD-200 in healthy adults and adults with rheumatoid arthritis.

Key facts

Who runs it
Lifordi Immunotherapeutics Inc.
Where
Torun and Warsaw, PolandSee the 2 sites
Registry title
A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis
Status
Recruiting
Phase
Phase 1
People taking part
40 people, planned
Started
6 Oct 2026
Expected to end
31 Oct 2027
Type of study
Interventional
Record updated
28 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults and adults with moderate to severe rheumatoid arthritis. It tests how safe different doses of LFD-200 are and how it works.

Age
18 years or older
Sex
All sexes can join
Disease stage
Moderate to severe rheumatoid arthritis (healthy people can also join)

Where in Poland

  • Medicover Integrated Clinical Services Sp. z o.o.Torun, PolandTaking people
  • Klinika Reuma Park Sp. z o.o. S.K.Warsaw, PolandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Safety and Effects of LFD-200 in Healthy People and People With Rheumatoid ArthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
28 August 2026